Cannabidiol in Developmental Epilepsy: Organoid-Guided Precision Medicine Across Critical Neurodevelopmental Windows

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• Epilepsy is a progressive network disorder causing cognitive decline and pharmacoresistance.
• Developmental epileptic encephalopathies are particularly challenging.
• Cannabidiol (CBD) is an adjunctive therapy for childhood epilepsies, but its use is limited by variable responses and incomplete understanding of its effects.

Purpose of the Study:

• To synthesize evidence on CBD's antiseizure and neuroprotective actions.
• To explore CBD's disease-modifying potential during critical neurodevelopmental windows.
• To utilize human brain organoids for precision therapeutic discovery in epilepsy.

Main Methods:

• Review of molecular, preclinical, and clinical evidence for CBD's mechanisms.
• Highlighting neurodevelopmental stages for CBD intervention.
• Employing human brain organoids to model cortical development and epilepsy.

Main Results:

• CBD modulates multiple targets, including GPCRs, adenosine signaling, TRP channels, GABAergic maturation, and neuroinflammation.
• Timely CBD intervention may prevent pathological network consolidation.
• Brain organoids enable stratification of CBD-responsive phenotypes and safety profiling.

Conclusions:

• Organoid-guided frameworks support personalized, developmentally informed CBD therapy.
• CBD has pleiotropic antiseizure and neuroprotective effects.
• This approach advances precision medicine for epilepsy, aiming to modify disease trajectories.